Effect of N-acetylcysteine on prevention of contrast-associated acute kidney injury in patients with STEMI undergoing primary percutaneous coronary intervention: a systematic review and meta-analysis of randomised controlled trials

ObjectiveSeveral studies evaluating the preventive effect of N-acetylcysteine (NAC) on contrast-associated acute kidney injury (CA-AKI) among patients with ST segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI) have suggested inconsistent resu...

Full description

Saved in:
Bibliographic Details
Published in:BMJ open 2020-10, Vol.10 (10), p.e039009-e039009
Main Authors: Guo, Zhaodong, Liu, Jin, Lei, Li, Xue, Yan, Liu, Liwei, Huang, Hao, Chen, Shiqun, Liu, Yong, Lin, Yingzhong, Tao, Jianhong, Xu, Qingbo, Wu, Keng, Zhang, Lingyu, Chen, Ji-Yan
Format: Article
Language:English
Subjects:
Acetylcysteine - therapeutic use
Acute Kidney Injury - chemically induced
Acute Kidney Injury - prevention & control
acute renal failure
Angioplasty
cardiology
Cardiovascular disease
Cardiovascular Medicine
coronary heart disease
coronary intervention
Creatinine
Data collection
Handbooks
Heart attacks
Hemodialysis
Humans
Intervention
Kidneys
Meta-analysis
Mortality
myocardial infarction
Percutaneous Coronary Intervention - adverse effects
Randomized Controlled Trials as Topic
Renal Dialysis
Software
ST Elevation Myocardial Infarction - surgery
Systematic review
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:ObjectiveSeveral studies evaluating the preventive effect of N-acetylcysteine (NAC) on contrast-associated acute kidney injury (CA-AKI) among patients with ST segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI) have suggested inconsistent results and that a systematic review and meta-analysis should be performed.DesignSystematic review and meta-analysis.Data sourcesPubMed, MEDLINE, EMBASE, ClinicalTrials.gov and the Cochrane Central databases were searched from inception to 15 November 2019.Eligibility criteriaRandomised controlled trials assessing use of NAC compared with non-use of NAC (eg, placebo) in preventing CA-AKI in patients with STEMI following PPCI were included.Data synthesisRelative risks with 95% CIs were pooled using a random-effects model. Evidence level of conclusions was assessed by Cochrane GRADE measure.ResultsSeven trials including 1710 patients were identified. Compared with non-use of NAC, use of NAC significantly reduced the incidence of CA-AKI by 49% (risk ratio (RR) 0.51, 95% CI 0.31 to 0.82, p
ISSN:2044-6055
2044-6055
DOI:10.1136/bmjopen-2020-039009